BCIQ Profiles

Company Profile Report

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat

Read the full 248 word article

How to gain access

Continue reading with a
two-week free trial.